Following his presentation at ACR 2020 we spoke with Ronald van Vollenhoven (Amsterdam University Medical Centers, Amsterdam, the Netherlands) regarding upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis. (Clinical Trial Identifier: NCT02706873). The abstract ‘Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks’ (ABSTRACT NUMBER: 0207) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What is the rationale for the use of JAK inhibitors in the treatment of rheumatoid arthritis (RA)? (0:25)
- How does upadacitinib fit into the current treatment paradigm for RA? (1:52)
- Could you give us an overview of the SELECT-EARLY study and its findings? (3:19)
- What have the latest data taught us about the long term efficacy and safety of upadacitinib? (4:27)
- What are the remaining gaps in our knowledge regarding the optimal use of upadacitinib in RA, and what further studies are planned? (5:35)
Disclosures: Research Support (institutional grants): BMS, GSK, Lilly, UCB. Support for Educational programs (institutional grants): Pfizer, Roche. Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB. Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual)
